Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units

Annals of Oncology

Volumn 10, Issue 4, 1999, Pages 449-453

  Petit, T ^a   Izbicka, E ^a   Lawrence, R A ^a   Bishop, W R ^b   Weitman, S ^a   Von Hoff, D D ^a  

^a CTRC Institute for Drug Development   (United States)

^b Institute for Drug Development ^*

Author keywords

Farnesyltransferase inhibitor; Human tumor cloning assay; SCH 66336

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; LONAFARNIB; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; CANCER RESISTANCE; COLONY FORMING UNIT; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; ONCOGENE RAS; OVARY CARCINOMA; PRIORITY JOURNAL;

EID: 0032932257     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008313232381     Document Type: Article

References (28)

1. Barbacid M. Ras genes. Annu Rev Biochem 1987; 56: 779-827.
2. Bos JL. The ras family and human carcinogenesis. Mutat Res 1988; 195: 255-71.
3. Bos JL. Ras oncogenes in human cancer: A review. Cancer Res 1989; 49: 4682-9.
4. Kalo K, Cox AD, Hisaka MM, Graham SM et al. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA 1992; 89: 6403-7.
5. Hancock JF, Magee AI, Childs JE, Marshall CJ. All ras protein are polyisoprenylated but only some are palmitoylated. Cell 1989; 57: 1167-77.
6. Willumsen BM, Norris K, Papageorge AG et al. Harvey murine sarcoma virus p21 ras protein: Biological and biochemical significance of the cysteine nearest the carboxy terminus. EMBO J 1984; 3:2581-5.
7. Gibbs JB. Ras C-terminal processing enzymes - new drug targets? Cell 1991: 65: 1-4.
8. Gibbs JB, Oliff A, Kohl NE. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 1994; 77: 175-8.
9. Bishop WR, Bond R, Petrin J, Wang L et al. Novel tricyclic inhibitors of farnesyl protein transferase. J Biol Chem 1995; 51: 30611-8.
10. Njoroge FG, Vibulbhan B, Rane DF et al. Structure-activity of 3-substituted N-(pyridinylacetyl)-4-(8-chloro-5,6-dihydro-IIH-benzo[5,6]cyclo-hepla[1,2-b] pyridin-11-ylidene)piperidine inhibitors of farnesyl-protein transferase: Design and synthesis of in vivo active antitumor compounds. J Med Chem 1997; 40: 4290-301.
11. Mallams AK, Njoroge FG, Doll RJ et al. Antitumor 8-chlorobenzocycloheptapyridines: A new class of selective, nonpeptidic, nonsulfhydryl inhibitors of Ras farnesylation. Bioorg Med Chem 1997; 5: 93-9.
12. Mallans AK, Rossman RR, Doll RJ et al. Inhibitors of farnesyl protein transferase. 4-amido, 4-carbamoyl, and 4-carboxamido derivatives of 1-(8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-y1)piperazine and 1-(3-bromo-8-chloro-6.11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-y1) piperazine. J Med Chem 1998:41:877-93.
13. Hamburger AW, Salmon SE. Primary bioassay of human myeloma stem cell. Science 1977; 197: 471.
14. Von Hoff DD, Sandbach J, Clark G et al. Selection of cancer chemotherapy for patient by an in vitro assay versus a clinician. J Nail Cancer Inst 1990; 82: 110-6.
15. Von Hoff DD, Kronmal R, Salmon SE et al. A Southwest Oncology Group study on the use of a human tumor cloning assay for predicting response in patients with ovarian cancer. Cancer 1991; 67: 20-7.
16. Hanauske A-R, Hilsenbeck SG, Von Hoff DD. The human tumor-cloning assay. In Schilsky RL, Milano GA, Ratain MJ (eds): Principles of Antineoplastic Drug Development and Pharmacology. New York: Markel Dekker 1996; 15-27.
17. Liu M, Bryant MS, Chen J et al. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and Wap-ras transgenic mice. Cancer Res 1998; 58: 4947-56.
18. Alberts D, Chen H. Tabular summary of pharmacokinetic parameters relevant to in vitro drug assay. In Salmon SE (ed): Human Tumor Stem Cells. New York: Alan R Liss 1980: 351-9.
19. Sebti SM, Hamilton AD. New approaches to anticancer drug design based on the inhibition of farnesyltransferase. Drug Disc Today 1988; 3: 26-33.
20. Barrington RE, Subler MA, Rands E et al. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol Cell Biol 1998; 18: 85-92.
21. James GL, Goldstein JL, Brown MS. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J Biol Chem 1995; 270: 6221-6.
22. Zhang FL, Kirschmeier P, Carr D et al. Characterization of Ha-Ras, N-Ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I. J Biol Chem 1997; 272: 10232-9.
23. Whyte DB, Kirschmeier P, Hockenberry TN et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 1997; 272: 14459-64.
24. Boguski MS, Mc Cormick F. Proteins regulating Ras and its relatives. Nature 1993; 366: 643-54.
25. James GL, Goldstein JL, Brown MS et al. Benzodiazepine peptidomimetics: Potent inhibitors of ras farnesylation in animals cells. Science 1993; 260: 1937-42.
26. Garcia AM, Rowell C, Ackermann K et al. Peptidomimetic inhibitors of Ras farnesylation and function in whole cells. J Biol Chem 1993; 268: 18415-8.
27. Kirschmeier P, Carr D, Gray K etal. SCH 66336, an orally bioavailable tricyclic farnesyl transferase inhibitor blocks anchorage-independent growth of ras-transformed fibroblasts and human tumor cell lines. Proc Annu Meet Am Assoc Cancer Res 1998; 39: 318.
28. Bryant MS, Liu M, Wang S et al. Pharmacokinetics of a potent orally bioavailable inhibitor of farnesyl protein transferase in the mouse, rat and cynomolgus monkey. Proc Annu Meet Am Assoc Cancer Res 1998; 39: 319.